NEOS THERAPEUTICS LP has a total of 30 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2006. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and environmental technology are RECEPTICON APS, PROCARE HEALTH IBERIA S L and INST FINLAY CT DE INVESTIGACION PRODUCCION DE VACUNAS Y SUEROS.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 12 | |
#2 | EPO (European Patent Office) | 5 | |
#3 | WIPO (World Intellectual Property Organization) | 4 | |
#4 | Australia | 2 | |
#5 | Canada | 2 | |
#6 | Mexico | 2 | |
#7 | China | 1 | |
#8 | Republic of Korea | 1 | |
#9 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Environmental technology | |
#4 | Computer technology | |
#5 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Microorganisms | |
#4 | Climate change adaptation technologies | |
#5 | Healthcare informatics | |
#6 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Tengler Mark | 28 |
#2 | Mcmahen Russell | 15 |
#3 | Mcmahen Russell Lee | 8 |
#4 | Lockhart Daniel | 5 |
#5 | Taskey Paul | 5 |
#6 | Teuscher Nathan | 5 |
#7 | Pathak Yashwant Vishnupant | 4 |
#8 | Daniel Lockhart | 2 |
#9 | Lee Mcmahen Russell | 2 |
#10 | Paul Taskey | 2 |
Publication | Filing date | Title |
---|---|---|
KR20190107655A | Effective Child Administration of Methylphenidate for the Treatment of ADHD | |
US2015004240A1 | Compositions and methods of making rapidly dissolving ionically masked formulations | |
WO2013003845A1 | Abuse resistant drug forms | |
EP2726066A1 | Dosage forms of amphetamine for oral administration | |
MX2009013019A | Modifying drug release in suspensions of ionic resin systems. | |
MX2007010541A | Compositions and methods of making sustained release liquid formulations. |